Cargando…
RNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid Proteins
An engineered RNase P-based ribozyme variant, which was generated using the in vitro selection procedure, was used to target the overlapping mRNA region of two proteins essential for human cytomegalovirus (HCMV) replication: capsid assembly protein (AP) and protease (PR). In vitro studies showed tha...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517104/ https://www.ncbi.nlm.nih.gov/pubmed/26114473 http://dx.doi.org/10.3390/v7072775 |
_version_ | 1782383148961628160 |
---|---|
author | Yang, Zhu Reeves, Michael Ye, Jun Trang, Phong Zhu, Li Sheng, Jingxue Wang, Yu Zen, Ke Wu, Jianguo Liu, Fenyong |
author_facet | Yang, Zhu Reeves, Michael Ye, Jun Trang, Phong Zhu, Li Sheng, Jingxue Wang, Yu Zen, Ke Wu, Jianguo Liu, Fenyong |
author_sort | Yang, Zhu |
collection | PubMed |
description | An engineered RNase P-based ribozyme variant, which was generated using the in vitro selection procedure, was used to target the overlapping mRNA region of two proteins essential for human cytomegalovirus (HCMV) replication: capsid assembly protein (AP) and protease (PR). In vitro studies showed that the generated variant, V718-A, cleaved the target AP mRNA sequence efficiently and its activity was about 60-fold higher than that of wild type ribozyme M1-A. Furthermore, we observed a reduction of 98%–99% in AP/PR expression and an inhibition of 50,000 fold in viral growth in cells with V718-A, while a 75% reduction in AP/PR expression and a 500-fold inhibition in viral growth was found in cells with M1-A. Examination of the antiviral effects of the generated ribozyme on the HCMV replication cycle suggested that viral DNA encapsidation was inhibited and as a consequence, viral capsid assembly was blocked when the expression of AP and PR was inhibited by the ribozyme. Thus, our study indicates that the generated ribozyme variant is highly effective in inhibiting HCMV gene expression and blocking viral replication, and suggests that engineered RNase P ribozyme can be potentially developed as a promising gene-targeting agent for anti-HCMV therapy. |
format | Online Article Text |
id | pubmed-4517104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-45171042015-07-28 RNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid Proteins Yang, Zhu Reeves, Michael Ye, Jun Trang, Phong Zhu, Li Sheng, Jingxue Wang, Yu Zen, Ke Wu, Jianguo Liu, Fenyong Viruses Article An engineered RNase P-based ribozyme variant, which was generated using the in vitro selection procedure, was used to target the overlapping mRNA region of two proteins essential for human cytomegalovirus (HCMV) replication: capsid assembly protein (AP) and protease (PR). In vitro studies showed that the generated variant, V718-A, cleaved the target AP mRNA sequence efficiently and its activity was about 60-fold higher than that of wild type ribozyme M1-A. Furthermore, we observed a reduction of 98%–99% in AP/PR expression and an inhibition of 50,000 fold in viral growth in cells with V718-A, while a 75% reduction in AP/PR expression and a 500-fold inhibition in viral growth was found in cells with M1-A. Examination of the antiviral effects of the generated ribozyme on the HCMV replication cycle suggested that viral DNA encapsidation was inhibited and as a consequence, viral capsid assembly was blocked when the expression of AP and PR was inhibited by the ribozyme. Thus, our study indicates that the generated ribozyme variant is highly effective in inhibiting HCMV gene expression and blocking viral replication, and suggests that engineered RNase P ribozyme can be potentially developed as a promising gene-targeting agent for anti-HCMV therapy. MDPI 2015-06-24 /pmc/articles/PMC4517104/ /pubmed/26114473 http://dx.doi.org/10.3390/v7072775 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yang, Zhu Reeves, Michael Ye, Jun Trang, Phong Zhu, Li Sheng, Jingxue Wang, Yu Zen, Ke Wu, Jianguo Liu, Fenyong RNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid Proteins |
title | RNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid Proteins |
title_full | RNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid Proteins |
title_fullStr | RNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid Proteins |
title_full_unstemmed | RNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid Proteins |
title_short | RNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid Proteins |
title_sort | rnase p ribozymes inhibit the replication of human cytomegalovirus by targeting essential viral capsid proteins |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517104/ https://www.ncbi.nlm.nih.gov/pubmed/26114473 http://dx.doi.org/10.3390/v7072775 |
work_keys_str_mv | AT yangzhu rnasepribozymesinhibitthereplicationofhumancytomegalovirusbytargetingessentialviralcapsidproteins AT reevesmichael rnasepribozymesinhibitthereplicationofhumancytomegalovirusbytargetingessentialviralcapsidproteins AT yejun rnasepribozymesinhibitthereplicationofhumancytomegalovirusbytargetingessentialviralcapsidproteins AT trangphong rnasepribozymesinhibitthereplicationofhumancytomegalovirusbytargetingessentialviralcapsidproteins AT zhuli rnasepribozymesinhibitthereplicationofhumancytomegalovirusbytargetingessentialviralcapsidproteins AT shengjingxue rnasepribozymesinhibitthereplicationofhumancytomegalovirusbytargetingessentialviralcapsidproteins AT wangyu rnasepribozymesinhibitthereplicationofhumancytomegalovirusbytargetingessentialviralcapsidproteins AT zenke rnasepribozymesinhibitthereplicationofhumancytomegalovirusbytargetingessentialviralcapsidproteins AT wujianguo rnasepribozymesinhibitthereplicationofhumancytomegalovirusbytargetingessentialviralcapsidproteins AT liufenyong rnasepribozymesinhibitthereplicationofhumancytomegalovirusbytargetingessentialviralcapsidproteins |